"The OCC product actually cuts out a stage when bone grafts are used .."
Are you concerned this is a disincentive for dentists to use the product. Dentists are small business operators with overheads and reputations for being strongly motivated to make profits (including over servicing). Patients rely on the advice of the dentist and would not be aware there is a lower cost procedure.
I have a little concern the revenue from this dental product will be slow and not as great as we are hoping for.
FDA significance, page-424
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $80.59M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 38.5¢ | $17.64K | 45.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 23269 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |